Literature DB >> 12396892

Ovarian autoimmune disease and ovarian autoantibodies.

Judith Luborsky1.   

Abstract

Detection of specific autoantibodies remains the most practical clinical and research marker of autoimmune disease. The lack of consensus on ovary specific antibodies as a marker for ovarian autoimmunity has clinical and research consequences. The objective of this review is to summarize the evidence for ovarian autoimmunity and the detection of ovary specific autoantibodies in humans. Evidence favors the presence of an autoimmune disease of the ovary. Ovarian autoantibodies are associated primarily with premature ovarian failure (POF) and unexplained infertility. Variations in detection of ovarian autoantibodies are likely to be due to study design elements such as antibody test format, antigen preparation, and criteria for study and comparison groups. In addition, multiple targets appear to be involved in ovarian autoimmunity including ovarian cellular elements and oocyte related antigens. Many studies only assess one target antigen, leaving individuals with ovarian autoimmunity unidentified. The next most significant advance in characterizing ovarian autoimmunity will be definitive identification of the specific antigens and development of standardized tests based on use of specific antigens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396892     DOI: 10.1089/152460902760360540

Source DB:  PubMed          Journal:  J Womens Health Gend Based Med        ISSN: 1524-6094


  20 in total

Review 1.  Mechanisms and models of immune tolerance breakdown in the ovary.

Authors:  Mickie H Cheng; Lawrence M Nelson
Journal:  Semin Reprod Med       Date:  2011-10-03       Impact factor: 1.303

2.  Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure.

Authors:  Seby L Edassery; Seerin V Shatavi; Jeremy P Kunkel; Charles Hauer; Cosima Brucker; Krishna Penumatsa; Yi Yu; James A Dias; Judith L Luborsky
Journal:  Fertil Steril       Date:  2010-06-01       Impact factor: 7.329

3.  The association of increased total glycosylated hemoglobin levels with delayed age at menarche in young women with type 1 diabetes.

Authors:  Kirstie K Danielson; Mari Palta; Catherine Allen; Donn J D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2005-10-04       Impact factor: 5.958

Review 4.  Multiplicity of molecular and cellular targets in human ovarian autoimmunity: an update.

Authors:  Eusebio S Pires
Journal:  J Assist Reprod Genet       Date:  2010-06-03       Impact factor: 3.412

5.  A study of ovarian autotransplantation without vascular a pedicle in rats.

Authors:  Ali Risvanli; Huseyin Timurkan; Nusret Akpolat; Irem Gulacti; Erdal Ulakoglu
Journal:  J Assist Reprod Genet       Date:  2006-12-02       Impact factor: 3.412

6.  fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

Authors:  Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Expert Opin Med Diagn       Date:  2011-05-01

7.  Autoantibodies to mesothelin in infertility.

Authors:  Judith L Luborsky; Yi Yu; Seby L Edassery; Jade Jaffar; Yuan Yee Yip; Pu Liu; Karl Eric Hellstrom; Ingegerd Hellstrom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-08-16       Impact factor: 4.254

8.  Can anti-ovarian antibody testing be useful in an IVF-ET clinic?

Authors:  Eusebio S Pires; Firuza R Parikh; Purvi V Mande; Shonali A Uttamchandani; Sujata Savkar; Vrinda V Khole
Journal:  J Assist Reprod Genet       Date:  2010-10-12       Impact factor: 3.412

9.  Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.

Authors:  Yi Yu-Rice; Seby L Edassery; Nicole Urban; Ingegerd Hellstrom; Karl Erik Hellstrom; Youping Deng; Yan Li; Judith L Luborsky
Journal:  Reproduction       Date:  2016-12-13       Impact factor: 3.906

10.  The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis.

Authors:  Danfeng Du; Xuelian Li
Journal:  Int J Clin Exp Med       Date:  2013-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.